The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The association between MRD and PFS in myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses his work, which helped to support the decision to use measurable residual disease (MRD) as an accelerated endpoint for FDA drug approvals in multiple myeloma (MM). The findings of his research demonstrate that MRD-negativity rates, measured with next-generation sequencing (NGS) and next-generation flow (NGF), strongly correlate with progression-free survival, offering an earlier indication of treatment efficacy. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
